T43.1X2A Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, initial encounter

Name of the Condition

• Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, initial encounter
• Technical term: T43.1X2A

Summary

This code describes intentional self-harm poisoning by monoamine-oxidase-inhibitor (MAOI) antidepressants during the initial encounter. MAOIs are a class of medications used to treat depression and other mental health conditions. The code applies when clinical documentation confirms intentional overdose of an MAOI and the encounter is the first time the patient is being seen for this event.

Causes

Intentional self-harm poisoning results from deliberate ingestion of an MAOI in excess of the prescribed dose with the intent to cause harm. This may involve taking the medication in a single large dose or over a short period. Adverse effects can occur due to the body's reaction to the drug, though poisoning implies a higher-than-intended dose.

Risk Factors

• History of mental health conditions, such as depression or suicidal ideation, that increase self-harm risk.
• Concurrent use of other medications that interact with MAOIs (e.g., certain antidepressants, pain relievers, or dietary supplements).
• Access to the medication without supervision or safeguards.
• Pre-existing conditions like cardiovascular disease or liver impairment that heighten adverse effect risk.

Symptoms

Symptoms may include:

• Altered mental status, confusion, or agitation.
• Hypertensive crisis (severe headache, rapid heart rate, chest pain).
• Nausea, vomiting, or abdominal pain.
• Seizures or loss of consciousness.
• Respiratory distress or failure.

Diagnosis

Diagnosis is based on clinical presentation, patient history, and laboratory tests. Documentation must confirm intentional self-harm and the initial encounter. Toxicology screens may identify the MAOI, and vital signs or neurological assessments help evaluate severity. The clinical context (e.g., suicidal intent) is critical for accurate coding.

Treatment Options

Treatment focuses on stabilizing the patient, removing the toxin, and managing complications. This may include activated charcoal, supportive care (e.g., airway management), and medications to control symptoms (e.g., antihypertensives). Psychiatric evaluation and intervention are essential for addressing the underlying intent.

Prognosis and Follow-Up

Prognosis depends on the dose, time to treatment, and patient factors. Early intervention improves outcomes. Follow-up includes monitoring for complications, psychiatric care, and safety planning. Long-term support may be needed to address mental health concerns.

Complications

Complications can include organ damage (e.g., liver or kidney failure), cardiovascular events (e.g., stroke), or permanent neurological impairment. Severe cases may be life-threatening.

Lifestyle & Prevention

Prevention involves secure medication storage, patient education on risks, and addressing underlying mental health conditions. Family or caregiver involvement may help reduce access to means of self-harm.

When to Seek Professional Help

Seek immediate medical attention if intentional overdose is suspected. Signs like altered consciousness, severe symptoms, or known self-harm intent require urgent care. Psychiatric support should be sought to address suicidal thoughts or behaviors.

Tips for Medical Coders

Document the intent (intentional self-harm) and encounter type (initial) clearly. Ensure the MAOI is identified as the causative agent. Code T43.1X2A is specific to initial encounters; subsequent care uses different codes. Verify that documentation supports the intentional nature of the poisoning.